Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jan;35(1):18-24.
doi: 10.1002/jca.21753. Epub 2019 Oct 30.

Delayed adverse events in male plateletpheresis donors: Initial insights on donor safety

Abhaykumar M Gupta  1 , Meenu Bajpai  1
Affiliations
Observational Study

Delayed adverse events in male plateletpheresis donors: Initial insights on donor safety

Abhaykumar M Gupta et al. J Clin Apher. 2020 Jan.

Abstract

Background: Minimal information is available regarding delayed adverse donor events (D-ADEs) in plateletpheresis donors. Proactive follow up of donors for D-ADEs is not done routinely by BTS. The aim of this study was to analyze frequency and type of D-ADEs and its correlation with contributory factors if any.

Methods: In this prospective observational study all eligible donors were contacted by telephone twice and asked about general wellbeing and questions specific to adverse donor events (ADEs). Donors were called at 24 hours and 2 weeks after donation. The ADEs were categorized in accordance with the International Society of Blood Transfusion standard guidelines.

Results: A total of 531 donors were analyzed in the study. D-ADEs were more common as compared to immediate ADEs (I-ADEs) (19.21% vs 5.46%, P < .0001). The most common D-ADEs were bruises (7.34%) and sore arms (3.58%). Localized D-ADEs in form of bruise and hematomas were more frequent as compared to systemic D-ADEs like fatigue and vaso-vagal reactions (16.01% vs 3.20% P < .0001). Repeat donors had a lower incidence of systemic D-ADEs (1.61% vs 6.96%, P = .001). Donors with weight ≤75 kg and platelet count ≤230 × 103 μL were more prone to systemic D-ADEs (P < .05). Citrate toxicity was more common in donors with weight ≤ 75 kg (P = .002).

Conclusions: Plateletpheresis procedures are relatively safer without any sequelae. D-ADEs are more common than I-ADEs. Localized D-ADEs are more frequent than systemic D-ADEs. First-time donors are more prone to D-ADEs than repeat donors.

Keywords: apheresis donor safety; delayed adverse donor events; hematoma; plateletpheresis; vaso-vagal reactions.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Rock G, Sutton DM. Apheresis: man versus machine. Transfusion. 1997;37:993-995.
    1. The trial to reduce alloimmunization to platelets study group (TRAP). Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion. N Engl J Med. 1997;337:1861-1869.
    1. Makar YF, Butler MO, Cockersole GM, Gabra G, Serevitch JM. National audit of citrate toxicity in plateletpheresis donors. Transfus Med. 2002;12:187-191.
    1. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998;38:938-943.
    1. Crocco Isabella FM, Garozzo G, Gandini AR, Gandini G, Bonomo P, et al. Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus. 2009;7:35-38.

Publication types

LinkOut - more resources